pharmaphorum

OCTOBER 12, 2022

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data generated from “omics” studies.

Genome 64

Genome Genomics DNA Drugs 64

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. billion in funding.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

pharmaphorum

DECEMBER 9, 2022

The new graduates – selected out of 75 applicants in a hotly contested application process – are working on a diverse array of digital health platforms including remote patient monitoring techniques, biomarkers, drug discovery and analytics tools, data annotation platforms, therapeutic-area data models, and novel RWE datasets.

Life Science 52

Life Science DNA Genomics Genome 52

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. Regulatory bodies are also taking note of the applications of AI in drug development.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. million and $38.8 million, respectively, as compared to $17.6

Genetics 105

Genetics Vaccination Vaccine DNA 105

The Pharma Data

OCTOBER 14, 2020

The AOP Orphan Group manufactures 80% of its drugs in Europe and has more than 20 subsidiaries and representative offices across the whole of Europe as well as in the United Arab Emirates and Israel. Food and Drug Administration granted Breakthrough Therapy designation to France-based Inventiva’s experimental NASH treatment lanifibranor.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52